- Home
- NEA vs SNY Comparison
NEA vs SNY Comparison
Compare NEA & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEA
- SNY
- Stock Information
- Founded
- NEA 2002
- SNY 1994
- Country
- NEA United States
- SNY France
- Employees
- NEA N/A
- SNY N/A
- Industry
- NEA Finance/Investors Services
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- NEA Finance
- SNY Health Care
- Exchange
- NEA Nasdaq
- SNY Nasdaq
- Market Cap
- NEA N/A
- SNY 123.6B
- IPO Year
- NEA N/A
- SNY N/A
- Fundamental
- Price
- NEA $10.82
- SNY $53.72
- Analyst Decision
- NEA
- SNY Buy
- Analyst Count
- NEA 0
- SNY 2
- Target Price
- NEA N/A
- SNY $62.50
- AVG Volume (30 Days)
- NEA 803.4K
- SNY 3.6M
- Earning Date
- NEA 01-01-0001
- SNY 04-24-2025
- Dividend Yield
- NEA 4.23%
- SNY 3.05%
- EPS Growth
- NEA N/A
- SNY 39.56
- EPS
- NEA N/A
- SNY 5.45
- Revenue
- NEA N/A
- SNY $48,817,552,946.00
- Revenue This Year
- NEA N/A
- SNY $5.35
- Revenue Next Year
- NEA N/A
- SNY $6.69
- P/E Ratio
- NEA N/A
- SNY $9.68
- Revenue Growth
- NEA N/A
- SNY N/A
- 52 Week Low
- NEA $9.20
- SNY $45.80
- 52 Week High
- NEA $11.37
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- NEA 47.41
- SNY 53.35
- Support Level
- NEA $10.53
- SNY $52.23
- Resistance Level
- NEA $10.78
- SNY $53.70
- Average True Range (ATR)
- NEA 0.16
- SNY 1.23
- MACD
- NEA 0.04
- SNY 0.39
- Stochastic Oscillator
- NEA 96.47
- SNY 98.61
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.